{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:52:02Z","timestamp":1785163922356,"version":"3.55.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the current prescribing patterns of statin therapy among outpatients with type 2 diabetes at Friendship Hospital, with a focus on alignment between treatment intensity with cardiovascular risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at Friendship Hospital from December 2022 to December 2023. Patient aged 40\u201375 years with type 2 diabetes mellitus who attended follow-up visits were included using stratified random sampling by treatment department. Clinical data were extracted from medical records to assess cardiovascular risk based on the 2023 American Diabetes Association guideline and to document statin use, intensity, treatment continuity and related factors. Multivariate logistic regression was performed to identify factors associated with whether or not patients were prescribed statins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 407 patients, 30.5% were classified as having established ASCVD, 55.6% as having high cardiovascular risk, and 99.8% of patients were eligible for indication of high intensity statin. Despite this, none received high-intensity statin. Most patients (77.4%) were prescribed moderate-intensity statins, 8.6% received low-intensity statins, and 14.0% were not prescribed any statin. A total of 58.5% of patients received uninterrupted statin prescriptions over one year, whereas 54.3% underwent changes in statin intensity during the follow-up period. Statin prescription (versus non-prescription) was significantly influenced by the treatment department, ASCVD status, and the presence of dyslipidemia (p\u2009&lt;\u20090.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although statin use was common, the intensity and continuity of treatment were often inconsistent with cardiovascular risks. The absence of high-intensity statin prescriptions in a population largely at very high risk may limit the potential benefits of lipid-lowering therapy. These findings highlight the need to strengthen adherence to guideline-directed statin therapy in the management of type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0343313","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:40:13Z","timestamp":1772217613000},"page":"e0343313","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Statin prescribing patterns in cardiovascular risk management among outpatients with type 2 diabetes: Real-world practices at a Vietnamese general hospital"],"prefix":"10.1371","volume":"21","author":[{"given":"Long","family":"Bui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Thi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung Hong","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7189","authenticated-orcid":true,"given":"Van Thi Thuy","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Thi Bich","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-4247","authenticated-orcid":true,"given":"Phuong T. Xuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"7","key":"pone.0343313.ref001","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic burden of cardiovascular disease in type 2 diabetes: a systematic review","volume":"21","author":"TR Einarson","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"pone.0343313.ref002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"TR Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"pone.0343313.ref003","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"J Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"7","key":"pone.0343313.ref004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/dc14-2498","article-title":"Cardiovascular and all-cause mortality over a 23-year period among chinese with newly diagnosed diabetes in the da qing IGT and diabetes study","volume":"38","author":"Y An","year":"2015","journal-title":"Diabetes Care"},{"issue":"11","key":"pone.0343313.ref005","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/jgs.12513","article-title":"Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review","volume":"61","author":"G Moreno","year":"2013","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"pone.0343313.ref006","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"P Gaede","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0343313.ref007","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"P Gaede","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"pone.0343313.ref008","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","article-title":"Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study","volume":"61","author":"J Oellgaard","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"pone.0343313.ref009","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"5","author":"K Ueki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0343313.ref010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"NA ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"9689","key":"pone.0343313.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(09)61478-1","article-title":"Intensive glucose control and cardiovascular outcomes","volume":"374","author":"JS Yudkin","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"pone.0343313.ref012","article-title":"Effect of multifactorial treatment targets and relative importance of hemoglobin A1c, blood pressure, and low-density lipoprotein-cholesterol on cardiovascular diseases in chinese primary care patients with type 2 diabetes mellitus: a population-based retrospective cohort study","volume":"6","author":"EYF Wan","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"pone.0343313.ref013","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-010-1864-z","article-title":"Intensified glucose lowering in type 2 diabetes: time for a reappraisal","volume":"53","author":"JS Yudkin","year":"2010","journal-title":"Diabetologia"},{"issue":"9607","key":"pone.0343313.ref014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"issue":"34","key":"pone.0343313.ref015","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"FLJ Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"24","key":"pone.0343313.ref016","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"SM Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"pone.0343313.ref017","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"140","author":"DK Arnett","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"pone.0343313.ref018","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert consensus decision pathway on the role of nonstatin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology solution set oversight committee","volume":"80","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"pone.0343313.ref019","unstructured":"Vietnam Ministry of Health. Guidelines for primary prevention of cardiovascular diseases. 2020."},{"key":"pone.0343313.ref020","unstructured":"Vietnam Ministry of Health. Guidelines for diagnosis and treatment of type 2 diabetes. 2020."},{"issue":"1","key":"pone.0343313.ref021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000275","article-title":"Evaluation of statin prescriptions in type 2 diabetes: india heart watch-2","volume":"4","author":"R Gupta","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"pone.0343313.ref022","volume-title":"Biostatistics: a foundation for analysis in the health sciences","author":"WW Daniel","year":"2018"},{"issue":"10","key":"pone.0343313.ref023","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.eprac.2023.07.001","article-title":"Trends and gaps in statin use for cardiovascular disease prevention in type 2 diabetes: a real-world study in Shanghai, China","volume":"29","author":"R Jing","year":"2023","journal-title":"Endocr Pract"},{"key":"pone.0343313.ref024","unstructured":"Lee B, Dumrongkitchaiporn K, Sriussadaporn S, Thongtang N. Statin Intensity Regimens in Thai Type 2 Diabetic Patients Who Achieved LDL-C Targets. 2017."},{"issue":"1","key":"pone.0343313.ref025","doi-asserted-by":"crossref","DOI":"10.4103\/jrms.JRMS_100_18","article-title":"Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice","volume":"24","author":"MA Hammad","year":"2019","journal-title":"J Res Med Sci"},{"key":"pone.0343313.ref026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/TCRM.S182716","article-title":"Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings","volume":"15","author":"MH Elnaem","year":"2019","journal-title":"Ther Clin Risk Manag"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:40:17Z","timestamp":1772217617000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343313"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0343313","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}